A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates

Journal of Perinatology

Volumn 26, Issue 2, 2006, Pages 120-124

  Christensen, R D ^a   Alder, S C ^b   Richards, S C ^a   Horn, J T ^a   Lambert, D K ^a   Baer, V L ^a  

^a McKay Dee Hospital Center   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

3 mercapto D valine; D penicillamine; ELBW; Retinopathy of prematurity

Indexed keywords

CREATININE; CUPRIMIME; PENICILLAMINE;

ACIDOSIS; APNEA; ARTICLE; BIRTH WEIGHT; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EXTREMELY LOW BIRTH WEIGHT; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; GESTATIONAL AGE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERCAPNIA; HYPERTENSION; HYPERTHERMIA; HYPOTENSION; HYPOTHERMIA; HYPOXEMIA; INCIDENCE; INTESTINE PERFORATION; LIVER TOXICITY; MALE; NEPHROTOXICITY; NEUTROPENIA; NEWBORN; NURSING CARE; PATIENT MONITORING; PILOT STUDY; PRACTICE GUIDELINE; RETROLENTAL FIBROPLASIA; SCORING SYSTEM; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING; COMPARATIVE STUDY; DIGESTIVE TRACT INTUBATION; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; MAXIMUM TOLERATED DOSE; RISK ASSESSMENT; TREATMENT OUTCOME; VERY LOW BIRTH WEIGHT;

BIRTH WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; INTUBATION, GASTROINTESTINAL; MALE; MAXIMUM TOLERATED DOSE; PENICILLAMINE; PILOT PROJECTS; RETINOPATHY OF PREMATURITY; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33646097000     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211440     Document Type: Article

References (29)

1. Phelps DL, ETROP Cooperative Group. The early treatment for retinopathy of prematurity study: Better outcomes, changing strategy. Pediatrics 2004; 114: 490-491.
2. Haines L, Fielder AR, Baker H, Wilkinson AR. UK population based study of severe retinopathy of prematurity: Screening, treatment, and outcome. Arch Dis Child Fetal Neonatal Ed 2005; 90: F240-F244.
3. http://www.nei.nih.gov/health/rop/index.asp.
4. Aiello LP. Vascular endothelial growth factor and the eye - past, present, and future. Arch Ophthalmol 1996; 114: 1252-1254.
5. Aiello LP. Vascular endothelial growth factor. 20th-century mechanisms, 21st-century therapies. Investig Ophthalmol Vis Sci 1997; 38: 1647-1652.
6. Polytarchou C, Papadimitriou E. Antioxidants inhibit angiogenesis in vivo through down-regulation of nitric oxide synthase expression and activity. Free Radic Res 2004; 38: 501-508.
7. Stone JS, Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 2002; 9: 231-238.
8. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: Role of NAD(P)H oxide. Mol Cell Biochem 2004; 264: 85-97.
9. Hunt JT, Lee VG, Liu EC, Moreland S, McMullen D, Webb ML et al. Control of peptide disulfide regioisomer formation by mixed cysteine-penicillamine bridges. Int J Peptide Protein Res 1993; 42: 249-258.
10. Matsubara T, Saura R, Hirohata K. Inhibition of human endothelial cell proliferation in vitro and neovasularization in vivo by D-penicillamine. J Clin Invest 1989; 83: 158-167.
11. Yoshida D, Ikeda Y, Nakazawa S. Copper chelation inhibits tumor angiogenesis in the experimental 9L gliosarcoma model. Neurosurgery 1995; 37: 287-292.
12. Pietraforte D, Mallozzi C, Scorza G, Minetti M. Role of thiols in the targeting of S-nitroso thiols to red blood cells. Biochemistry 1995; 34: 7177-7185.
13. McBrien NA, Norton TT. Prevention of collagen crosslinking increases form-deprivation myopia in tree shrew. Exp Eye Res 1994; 59: 475-486.
14. Siemeister G, Schnurr B, Mohrs K, Schachtele C, Marme D, Martinyaron G. Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli. Biochem Biophys Res Commun 1996; 222: 249-255.
15. Lakatos L, Kover B, Oroszlan GY, Vekerdy ZS. Penicillamine therapy in ABO hemolytic disease of the newborn infant. Eur J Pediatr 1976; 123: 133-137.
16. Lakatos L, Hatvani I, Oroszlan G, Balla G, Karmazsin L, Alaka O et al. Controlled trial of D-penicillamine to prevent retinopathy of prematurity. Acta Paediatr Hungar 1986; 27: 47-56.
17. Phelps DL, Lakatos L, Watts JL. Penicillamine for preventing retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev 2001; 1: CD001073.
18. An International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity Revisited. Arch Ophthalmol 2005; 123: 991-995.
19. Good WV, Hardy RJ. The multicenter study of early treatment for retinopathy of prematurity (ETROP). Ophthalmology 2001; 108: 1013-1014.
20. Gilbert C, Fielder A, Gordillo L, Guinn G, Semiglia R, Visintin P et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: Implication for screening programs. Pediatrics 2005; 115: E518-e525.
21. Phelps DL, Watts JL. Early light reduction to prevent retinopathy of prematurity in very low birth weight infants. In: The Cochrane Library, Issue 1, 1997. Oxford: Update Software.
22. STOP-ROP Multicenter Trial. Supplemental therapeutic oxygen for prethrehold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. Pediatrics 2000; 105: 295-310.
23. Saugstad OD. Oxygen for newborns: How much is too much? J Perinatol 2005; 25(Suppl 2): S45-S49.
24. Alva JA, Inuela-Arispe ML. Notch signaling in vascular morphogenesis. Curr Op Hematol 2004; 11: 278-293.
25. Lakatos L, Kover B, Vekerdy ZS, Dvoracsdk E. D-penicillamine therapy in neonatal jaundice: Comparison with phototherapy. Acta Paediatr Acad Sci Hungar 1976; 17: 93-102.
26. Koranyi G, Kovacs J, Voros I. Penicillamine treatment of hyperbilirubinemia in preterm infants. Acta Paediatr Acad Sci Hungar 1978; 19: 9-16.
27. Drosos AA, Geogriou P, Politi EN, Voulgari PV. D-penicillamine in early rheumatoid arthritis. Clin Exper Rheumatol 1997; 15: 580.
28. Pinter R, Hogge WA, McPherson E. Infant with severe penicillamine embryopathy born to a woman with Wilson disease. Am J Med Genet A 2004; 128: 294-298.
29. Oga M, Matsui N, Anai T, Yoshimatsu J, Inoue I, Miyakawa I. Copper disposition of the fetus and placenta in a patient with untreated Wilson's disease. Am J Obstet Gynecol 1993; 169: 196-198.